Corrigendum to "Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis" [Radiother. Oncol. 187 (2023) 109839].

Kubeczko, Marcin; Jarzab, Michal; Gabrys, Dorota; Krzywon, Aleksandra; Cortez, Alexander J; Xu, Amy J

Kubeczko, Marcin; Jarzab, Michal; Gabrys, Dorota; Krzywon, Aleksandra; Cortez, Alexander J; Xu, Amy J.

Afiliação

Kubeczko M; Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland. Electronic address: marcin.kubeczko@io.gliwice.pl.
Jarzab M; Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland.
Gabrys D; Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland.
Krzywon A; Department of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland.
Cortez AJ; Department of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Poland.
Xu AJ; Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York City, USA.

Radiother Oncol ; 194: 110188, 2024 May.

Article em En | MEDLINE | ID: mdl-38447357

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Radiother Oncol Ano de publicação: 2024 Tipo de documento: Article País de publicação: Irlanda

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google